The people driving StemGen's mission to transform cancer treatment
Chairman of the Board
Born in Chiari (Italy) in 1964. He holds a degree in Business Administration from Bocconi University in Milan.
With over 30 years of experience in management consulting, he has supported the leadership and ownership of more than 100 Italian, European, and global companies across a wide range of industries, including manufacturing and industrial components, consumer goods, pharmaceuticals, information technology, publishing, and private equity. His work has focused on value creation through working capital optimization, performance improvement, organizational design, industrial planning, and corporate turnaround initiatives.
He served as Managing Director of REL Consultancy Group in Italy, later assuming responsibility for European clients in the consumer goods sector. He subsequently joined KPMG and later became Director at Sinergetica, a leading Italian consulting firm founded by Bruno Ermolli.
From 2022 to June 2025, he was Partner at Excellence Consulting in Milan. Since July 2025, he has been General Manager of the San Carlo Multi-specialty Clinic in Paderno Dugnano (Milan).
Since July 2024, he has also served as Chairman of Stemgen S.p.A., a biotech company focused on the development of therapies for rare diseases.
Member of the Board
Angelo L. Vescovi, born April 24th 1962 near Bergamo (Italy), M.Sc. in Biology at the University of Milan – Statale in 1987, after his post-doctoral fellowship at the Foothills Hospital Dept. of Pathology in Calgary Canada, becomes Head of the Neuropharmacology Unit at the Istituto Neurologico in Milan. Back to Calgary in 1999, he is designated Vice-director of Neurospheres ltd. Co-director of the Stem Cell Research Institute at the San Raffaele Hospital in Milan from 2001 to 2006, he is currently Associate Professor of Cell Biology at the University of Milan-Bicocca in Italy, scientific director of the non-profit Neural Stem Cells Bank in Terni (Italy) and Head of the Nanomedicine&Tissue Engineering Unit at the Ca’ Granda – Niguarda Hospital in Milan.
His major research fields are the cancer stem cells and neural stem cell studies for the therapy of neurodegenerative diseases, ischemias and spinal cord injuries, with a focus on gliomas and glioblastomas, ALS, Multiple Sclerosis, Alzheimer’s and Parkinson’s diseases. He has authored more than a hundred peer-reviewed papers (including Science, Nature, Nature Medicine, Nature Biotechnology, Nature Neuroscience, Proceedings of the National Academy of Science, some of which averagely cited more than 200 times) and book chapters, with a total h-index of thirty-three.
Due to his expertise in the field and his attention to the bio-ethical aspects of the subject, he was called in as Emeritus Speaker at the National Academy of Science (Accademia dei Lincei) and at the World Economic Forum in 2000, consultant for the National Committee on Stem Cells of the Italian Ministry of Health and of the House of Lords British Committee on Stem Cells, unique expert for the European Commission and member at the Pontifical committee on stem cells of the Vatican State.
Since January 1st 2010 he has become Scientific Director of the Hospital Casa Sollievo della Sofferenza in San Giovanni Rotondo.
Member of the Board
Mamber of the Board
Michael Rowan is a former Chief Executive Officer of Active Energy Group PLC (AEG), a London-based renewable energy company, having been appointed in July 2018.
Michael is a qualified solicitor, qualified investment manager and successful corporate financier with a broad range of international commercial and legal experience.
After graduating from the University of Cambridge, he practised as a solicitor at Linklaters in London, Hong Kong and New York, working with leading global financial institutions. He then moved to Merrill Lynch International in London and New York, where he became a director of Equity Capital Markets, with responsibility for origination, execution and commercial negotiation of equity and equity-linked transactions, including major privatisations in the UK and EMEA regions.
Since then, Michael has held senior roles within the venture capital and mid & small cap broking sectors in London and Hong Kong. More recently, he was Business Development Director and an Investment Manager at JM Finn & Co and he continues to be involved in private companies which specialise in investing in international micro capital and seed financing opportunities. He was appointed as Chief Executive Officer in July 2018
Member of the Board
Dr. Jessica Diana Rosati is a molecular and cellular biologist who earned her PhD in Genetics and Molecular Biology and a specialization in Medical Genetics. Her research focuses on rare genetic and neurodegenerative diseases, including disorders such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), and syndromic neurodevelopmental conditions. She leverages patient-specific induced pluripotent stem cells (iPSCs) to model disease mechanisms and identify therapeutic targets.
Her work is strongly oriented toward translational research, with a particular emphasis on drug repurposing as a strategy to accelerate the development of treatments for currently incurable conditions. She has authored numerous peer-reviewed publications in international journals, contributing to advances in disease modeling, stem cell biology, and therapeutic discovery.
She is Head of the Cellular Reprogramming Unit at Fondazione IRCCS Casa Sollievo della Sofferenza and Associate Professor of Applied Biology.
Clinical Operations Manager
Head of Clinical Research and Development: planning, coordination and oversight of clinical development of investigational new products in Glioblastoma.
Chief Strategy Officer (CSO)
Brent holds regular meetings with the CEO and is responsible for making strategic decision on drug development, pipeline selection, patent planning and liaisons with North American corporations. Brent has over 20 years of experience in advising biotech firms in NorthAmerica and Europe. He has also held various professorship roles at universities across the US and Australia, currently being a tenured professor in the Neurosurgery Department at the University of Florida. Brent holds a PhD in anatomy from the University of Calgary and serves as a scientific advisor to EriVanBio.
Alberto Visioli is a researcher and scientific contributor at StemGen, with expertise in cancer biology and glioblastoma research. His work focuses on the role of cancer stem cells in tumor initiation, progression, and therapeutic resistance, contributing to the development of innovative differentiation-based therapies.
He has co-authored multiple peer-reviewed publications in the field of oncology and stem cell biology, particularly on glioblastoma stem cells and their molecular characterization. His research activity supports the advancement of StemGen’s proprietary drug discovery platform aimed at targeting the root causes of aggressive solid tumors.